Table 1.

Characteristics of ALLHAT chlorthalidone, amlodipine, and lisinopril participants at baseline and during follow-up by baseline eGFR and antihypertensive treatment group

CharacteristicNormal or Increased eGFRMild Reduction in eGFRModerate/Severe Reduction in eGFR
(≥90 ml/min per 1.73 m2)(60-89 ml/min per 1.73 m2)(<60 ml/min per 1.73 m2)
CALCALCAL
Baseline
 sample size360622452176819947684811256514791501
 age (yr), mean (SD)63.4 (6.4)63.3 (6.6)63.3 (6.4)67.2 (7.4)67.4 (7.5)67.3 (7.5)70.8 (7.9)70.8 (7.6)70.6 (7.9)
 black, n (%)1825 (50.6)1138 (50.7)1079 (49.6)2491 (30.4)1472 (30.9)1475 (30.7)701 (27.3)388 (26.2)422 (28.1)
 women, n (%)1697 (47.1)1080 (48.1)975 (44.8)3657 (44.6)2104 (44.1)2144 (44.6)1346 (52.5)811 (54.8)747 (49.8)
 SBP (mmgHG), mean (SD)145.8 (15.2)145.7 (15.7)146.3 (15.1)146.2 (15.8)146.3 (15.6)146.3 (15.5)146.9 (16.3)146.1 (16.3)146.8 (16.4)
 DBP (mmgHG), mean (SD)84.9 (9.7)84.7 (9.9)85.2 (9.4)84.1 (10.0)84.0 (10.2)84.1 (10.0)82.5 (10.5)82.4 (10.4)82.8 (10.6)
 eGFR (ml/min per 1.73 m2), mean (SD) 102.6 (13.0)102.7 (12.9)102.8 (13.2)75.1 (8.1)75.2 (8.0)75.1 (8.1)50.1 (8.7)50.6 (8.5)50.1 (8.6)
 diabetic, n (%)1794 (51.5)1104 (51.0)1074 (50.9)2976 (38.0)1755 (38.8)1722 (37.5)953 (39.5)548 (39.1)529 (37.5)
Follow-up in-trial at 4 yr
 sample sizea2244143812795197307329611482842796
 SBP (mmgHG), mean (SD)133.5 (15.2)134.7 (14.5)b135.7 (17.4)c133.7 (15.6)134.6 (14.7)c135.3 (17.0)c135.5 (17.2)135.9 (17.1)136.5 (18.3)
 DBP (mmgHG), mean (SD)76.8 (9.5)76.5 (9.0)77.6 (10.1)b76.5 (9.6)75.8 (9.6)c76.3 (10.2)75.7 (10.0)74.2 (9.8)c75.8 (11.2)
 Taking statins, n (%)a823 (30.6)489 (28.8)503 (32.1)2074 (33.8)1259 (34.7)1179 (33.3)605 (34.1)332 (33.2)320 (32.7)
 eGFR (ml/min per 1.73 m2), mean (SD)d86.9 (18.4)93.2 (18.5)c88.4 (18.4)b68.8 (14.4)73.0 (14.7)c69.1 (14.7)48.2 (14.3)51.5 (15.2)c48.3 (14.2)
  • A total of 31,350 patients participated in the ALLHAT trial. Comparisons are with the chlorthalidone group. ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; eGFR, estimated GFR; C, chlorthalidone; A, amlodipine; L, lisinopril; SBP, systolic blood pressure; DBP, diastolic blood pressure.

  • a The sample size is based on the number of participants with SBP/DBP measurements. The percentage of participants taking statins is based on participants with a visit, and the denominators are larger than the indicated sample size. For the year-4 percentage of participants taking statins, sample sizes are as follows: normal or increased eGFR: 2687 for C, 1699 for A, and 1568 for L; mild reduction in eGFR: 6139 for C, 3626 for A, and 3539 L; and moderate reduction in eGFR: 1775 for C, 999 for A, and 980 for L.

  • b P<0.05.

  • c P<0.01.

  • d Due to participants with missing eGFR values, the year-4 sample sizes for mean eGFR are as follows: normal or increased eGFR, 1996 for C, 1247 for A, and 1098 for L; mild reduction in eGFR: 4662 for C, 2741 for A, and 2625 for L; and moderate reduction in eGFR: 1278 for C, 706 for A, and 662 for L.